MG
REGN icon

Marex Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Marex Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$243K Sell
389
-1,350
-78% -$919K ﹤0.01% 941
2026
Q1 		$1.34M Sell
1,739
-29,450
-94% -$22.5M 0.01% 382
2025
Q4 		$24.1M Sell
31,189
-19,769
-39% -$13.4M 0.15% 113
2025
Q3 		$28.7M Sell
50,958
-475
-0.9% -$269K 0.2% 96
2025
Q2 		$27M Sell
51,433
-19,435
-27% -$10.8M 0.23% 84
2025
Q1 		$44.9M Buy
70,868
+603
+0.9% +$415K 0.86% 27
2024
Q4 		$50.1M Buy
70,265
+35,062
+100% +$29.4M 0.85% 26
2024
Q3 		$37M Buy
+35,203
New +$39.2M 0.84% 31
2024
Q1 		– Sell
-25,216
Closed -$22.1M – 644
2023
Q4 		$22.1M Buy
+25,216
New +$20.8M 0.87% 28
2023
Q1 		– Sell
-330
Closed -$238K – 316
2022
Q4 		$238K Buy
+330
New +$243K 0.03% 215

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Marex Group's REGN Position: Q2 2026 in Review

Marex Group reduced its Regeneron Pharmaceuticals (REGN) stake by 78% in Q2 2026, selling an estimated $919K and leaving 389 shares worth $243K. The position accounts for ﹤0.01% of the portfolio, ranked #941.

Marex Group first reported a position in REGN in Q4 2022 and has held it in 10 quarters since. The position peaked at $50.1M in Q4 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Marex Group held 389 shares of Regeneron Pharmaceuticals worth $243K as of Q2 2026.
  • Marex Group sold 1,350 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $919K.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Marex Group's portfolio in Q2 2026, its #941 holding.
  • Marex Group first reported a position in Regeneron Pharmaceuticals in Q4 2022 and has held it in 10 quarters since.
  • Marex Group's Regeneron Pharmaceuticals position peaked at $50.1M in Q4 2024.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.